Molecular Formula | C17H11N3O6S |
Molar Mass | 385.35 |
Density | 1.54±0.1 g/cm3(Predicted) |
Boling Point | 624.1±55.0 °C(Predicted) |
Solubility | DMSO : 31 mg/mL (80.45 mM) |
Appearance | powder |
Color | white to beige |
pKa | 0.30±0.33(Predicted) |
Storage Condition | Sealed in dry,2-8°C |
In vitro study | ML221 is a potent apelin/APJ functional antagonist, inhibiting apelin-13-mediated activation of APJ, with IC 50 s of 0.70 μM in the cAMP assay, and 1.75 μM in the β-arrestin assay, and EC 80 of 10 nM in both assays. ML221 is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor (IC 50 , >79 μM) in cells. ML221 displays limited cross reactivity against a range of GPCRs except the κ-opioid and benzodiazepinone receptors (<50/<70%I at 10 μM). |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.595 ml | 12.975 ml | 25.95 ml |
5 mM | 0.519 ml | 2.595 ml | 5.19 ml |
10 mM | 0.26 ml | 1.298 ml | 2.595 ml |
5 mM | 0.052 ml | 0.26 ml | 0.519 ml |
biological activity | ML221 is an apelin (APJ) antagonist that inhibits apelin-13 of APJ-mediated activation, in the cAMP assay and the β-arrestin assay, the IC50 values were 0.70 μm and 1.75 μm, respectively, and the EC80 value was 10 nM. |
Target | IC50: 1.75 μm (APJ, cell-based) |